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Viewpoint

Clinician investigators and biomedical scientists share a fundamental obligation to produce
new knowledge that can lead to better treatments or cures for human disease. Conflicts of
interest (COIs) occur when professional responsibilities and altruistic goals are influenced
by an outside interest that biases clinical judgement or interpretation of data. The public
exposure of a failure to disclose COIs in clinical or translational research can lead to a loss
of confidence in the medical profession and in scientific discovery, respectively. The
Sunshine Act was seen as mitigating the lack of transparency in COI reporting by requiring
the pharmaceutical and device industries to disclose all payments to physicians and
teaching hospitals through the Open Payment program, a public and searchable database
of industry payments. This database has certainly helped, but problems persist, as
illustrated by front-page articles in the New York Times describing how undeclared COIs
have roiled two major areas of medical research. The first New York Times reports detailed
the failure of a top cancer researcher and senior administrator at Memorial Sloan Kettering
Cancer Center to disclose over $3.0 million in compensation from industry (1). A follow-up
report noted that this high level of remuneration was not unusual for influential physicians
who serve on industry advisory boards (2). The second series of articles focused on a
former Harvard physician-scientist and […]
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linician investigators and biomedical
scientists share a fundamental obligation
to produce new knowledge that can lead
to better treatments or cures for human
disease. Conflicts of interest (COIs) occur
when professional responsibilities and
altruistic goals are influenced by an outside
interest that biases clinical judgement or
interpretation of data. The public exposure
of a failure to disclose COIs in clinical or
translational research can lead to a loss of
confidence in the medical profession and in
scientific discovery, respectively. The Sunshine Act was seen as mitigating the lack of
transparency in COI reporting by requiring
the pharmaceutical and device industries
to disclose all payments to physicians and
teaching hospitals through the Open Payment program, a public and searchable
database of industry payments. This database has certainly helped, but problems
persist, as illustrated by front-page articles
in the New York Times describing how
undeclared COIs have roiled two major
areas of medical research.
The first New York Times reports
detailed the failure of a top cancer researcher and senior administrator at Memorial
Sloan Kettering Cancer Center to disclose
over $3.0 million in compensation from
industry (1). A follow-up report noted that
this high level of remuneration was not
unusual for influential physicians who
serve on industry advisory boards (2). The
second series of articles focused on a former Harvard physician-scientist and stem
cell biologist who had failed to disclose his
association with a biotechnology company
(3). After a five-year review, Harvard Medical School and Brigham and Women’s Hospital (HMS-BWH) called for the retraction

of 31 of his studies due, not to COIs, but to
serious concerns regarding the integrity of
data showing, in part, that c-kit+ stem cells
could regenerate damaged heart (4). These
two very different but equally high-profile
events provide useful case studies of the
adverse consequences that COIs can have
on the integrity of research and can help
guide development of improved reporting
and oversight structures.
First, the Memorial Sloan Kettering
case points out how academic institutions
and professional associations often turn
a blind eye to tracking and quantifying
COIs, particularly when the conflict is held
by a senior leader or a well-funded investigator. A failure to look for COIs and to
appropriately regulate them is all too common across many professional societies.
For example, the published policies of the
National Comprehensive Cancer Network
(NCCN) stipulate that authors of NCCN
clinical guidelines may not have financial
conflicts with the pharmaceutical industry
that exceed a single payment of $20,000/
year or aggregate payments of greater than
$50,000/year (5). A recent study found,
however, that 86% of guideline authors
had at least one conflict and that eight of
125 authors had received payments over
the benchmark levels (6). Societies have
also failed to establish useful regulations
for members of guideline committees. For
example, the NCCN precludes members
of guideline-writing committees from voting when they have a COI, but allows the
conflicted members to stay in the room
during those discussions at the discretion
of the chair (5). In some cases, the conflicted panel members are even allowed to
participate in the discussion. The NCCN
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guideline committees also need only have
51% of its members to be free of conflicts,
raising the concern that a panel in which
nearly half its members are conflicted
would be hard-pressed to avoid bias.
The Harvard/Brigham and Women’s
Hospital case demonstrates a second limitation of the Open Payment system — that
it does not capture payments made to physician-scientists who do not maintain a
medical license or to nonphysician investigators. Furthermore, companies that do
not yet produce an FDA-approved product
need not report payments to researchers.
The Open Payment system also does not
track the number of relevant patents that
an investigator has filed with the US patent office, an important metric because
it marks the intent of a faculty member
to commercialize intellectual property at
a later point in time. Thus, while current
COI policies capture the “conflict” of a
practitioner who attends a dinner sponsored by a pharmaceutical company, they
fail to identify substantive conflicts among
investigators who are leading clinical trials
that might alter the care of patients.
A third flaw in COI policies at many
academic institutions is a failure to properly oversee participation in clinical trials
by investigators who have commercialized their intellectual property and, as a
result, have equity in the study sponsor. An
absence of oversight often leads to investigators participating in clinical studies that
lack rigor in trial design, data collection,
and/or are prone to overinterpretation of
“encouraging” data buried in clinical endpoints that were not prespecified. In this
regard, two recent reviews on the use of
cardiac stem cells for regenerating heart
muscle pointed out that recent stem cell trials were rife with COIs (7, 8). For example,
studies published in high-impact journals
by investigators having an equity interest in
the sponsoring entity or in a collaborating
or contributing company reported salutary
benefits of cell therapy in clinical trials that
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Recommendations for improving disclosure and oversight
of conflicts
1. Published disclosures of COIs could be more meaningful if they divulged the amount of money
received from relevant commercial entities. When possible, authors should reconcile these
numbers with the Open Payment database.
2. Ownership in a private or public biotechnology company should be included in all disclosures
as well as the value of the equity or the percentage of issued stock that is held.
3. Published patent applications filed with the US patent office should be included as
potential COIs.
4. Guideline- and consensus-writing committees should exclude members with COIs or ask
them to resolve their COIs before joining the committee. When that is not possible, those with
COIs should be excused from the room during relevant discussions. The time-honored excuse
that the best clinicians consult for every company because their opinions are so highly valued
and that they therefore should not be excluded from writing committees is not a valid reason
for ignoring the problems inherent with COIs.
5. A physician holding equity in a private or public biotechnology company or who serves as a
director of a company should not participate as an investigator in any clinical trial sponsored
by that company nor be a lead author on academic publications that report the study results.
This is already a mandate at some, but far too few, academic centers in the US, and even when
present it may be ignored.
6. Wherever possible, investigational new drug–enabling preclinical studies should be carried
out by a clinical research organization and data analysis performed by an independent statistician, not by a trainee in the principal investigator’s laboratory.
7. Journal editors as well as guest editors must be free of all COIs, including equity and patents.
Publication committees should raise questions when there is an imbalance in the types or outcomes of studies published in their own journal as compared with those published by competitors. Furthermore, lead editors should be judicious in submitting research articles to their own
journal, limiting their submissions as far as possible to editorials and policy statements.
8. Academic institutions, publishers, and professional organizations must all share in the
responsibility to ensure that COIs are appropriately reported, fairly adjudicated, and dealt with
in a consistent manner.

enrolled fewer than 20 patients per treatment group (9–11), lacked concordance in
critical baseline demographic data (10),
did not include a control group (9, 12), and/
or reported efficacy in the absence of a
measured change in ventricular function
(11). In fact, a randomized clinical trial that
demonstrated a benefit of cardiac stem
cells was subsequently retracted by the
publisher because of questions regarding
the validity of the data (13).
Finally, professional societies that support journals bear responsibility for making sure that the editors and reviewers are
made aware of all author COIs before publishing consensus documents. This is illustrated by a 2017 consensus statement on
cardiomyocyte regeneration. The authors
concluded that bone marrow–derived
“c-kit+ cells or mesenchymal stem cells
3972

may confer structural or functional benefits” (14). Half of the authors disclosed an
equity interest in a related biotechnology
company, one author failed to note that
he had founded a stem cell company, and
a second author did not disclose that he
had filed multiple stem cell patents, information that might have given pause to the
reviewers and the editors if it were known
during the review process.
How can academic institutions, professional associations, and publishers
redefine the ground rules for the disclosure
and oversight of COIs in order to stem this
growing problem? We propose that a few
simple rules could go a long way toward
increasing the public’s trust, as detailed in
Recommendations for improving disclosure
and oversight of conflicts.
The growing number of reported COIs
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and our failure to properly manage them
threatens the integrity of the scientific process insofar as it has the potential to bias
scientific communications, which in turn
will erode public trust in the scientific community. This statement notwithstanding,
COI guidelines must not be so restrictive
that they shackle academic freedom and
stifle the entrepreneurial spirit of investigators. The scientific community must
seek a transparent middle ground. The
guidelines proposed herein may be viewed
as too strident by some and too lenient by
others, but they will hopefully serve as a
starting point for national discussions with
the goal of deriving new and innovative
policies that are fair but also enforceable.
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